COEGIN — Coegin Pharma AB Income Statement
0.000.00%
Last trade - 00:00
- SEK45.97m
- SEK40.42m
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | Interim Report | ARS | PRESS |
Standards: | SAS | SAS | — | SAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.574 | 0 | 0 | 0 | — |
Cost of Revenue | |||||
Gross Profit | 0.574 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 14.3 | 46.3 | 27.2 | 34.7 | 27.8 |
Operating Profit | -13.8 | -46.3 | -27.2 | -34.7 | -27.8 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -26.7 | -46.2 | -27.1 | -35.2 | -28 |
Provision for Income Taxes | |||||
Net Income After Taxes | -26.7 | -46.2 | -27.1 | -35.2 | -28 |
Net Income Before Extraordinary Items | |||||
Net Income | -26.7 | -46.2 | -27.1 | -35.2 | -28 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -26.7 | -46.2 | -27.1 | -35.2 | -28 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -15 | -29.4 | -3.83 | -4.43 | -2.71 |
Dividends per Share |